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Objectives: The purpose of this study was to evaluate the relative risks and advantages of using external jugular vein (EJV)
patch, compared with polytetrafluoroethylene (PTFE) patch, during carotid endarterectomy. The primary end point was
the relevant neurologic complication rate (RNCR; fatal or disabling stroke) at any time during follow-up. Secondary end
points included stroke-free survival, 30-day and long-term mortality, recurrent stenosis rate (>50%), occlusion, patch
infection, aneurysm formation, and other local complications.
Methods: The study, a prospective randomized clinical trial carried out at a single center, was divided into two 3-year
phases: December 1996 to March 1999, when patients were enrolled, and March 1999 to March 2002, which was the
follow-up period. Inclusion criteria included an external jugular vein suitable for patching, defined as vein diameter 3 mm
or larger and absence of collateral vessels noted on preoperative color duplex ultrasound scans. Patients were prospectively
randomized 1:1 to receive either the EJV (n  80; group A) or synthetic (n  80; group B) patch.
Results: Carotid endarterectomy and patching was performed by one surgeon. At 30 months the RNCR-free rate,
analyzed with the Kaplan-Meier method, was 98.7% for group A (1 ipsilateral lethal stroke) and 94.6% for group B (4
ipsilateral disabling strokes), and remained stable to 60 months. No statistical difference was observed with the log-rank
test. Stroke-free survival rate was 100% for group A and 98.7% for group B at 1 year, 98.7% for group A and 93.6% for
group B (1 ipsilateral minor stroke) at 30 months, and was unchanged at 60 months. Life table analysis demonstrated
freedom from significant recurrent stenosis (>50%) of 97.5% for both groups at 6 months, 93.6% for group A and 92.2%
for group B at 30 months, and 90.2% for group A and 86.7% for group B at 60 months. No statistical difference was
observed with the log-rank test. In no patients was recurrent stenosis greater than 70%. No aneurysm formation was
noted during follow-up.
Conclusions: We can conclude, with the power limitation of the study, that carotid endarterectomy can be safely performed
with either the EJV or PTFE patch. Advantages of the EJV for carotid angioplasty include no cost for material, low risk
for graft infection, and preservation of the saphenous vein. (J Vasc Surg 2003;38:1232-40.)
Carotid endarterectomy (CEA) reduces the long-term
risk for stroke in patients with severe symptomatic or
asymptomatic carotid stenosis.1-3 Review of randomized
trials of closure during CEA suggests that routine patching
is better than primary closure, because it is associated with
lower rates of postoperative stroke and late recurrent ste-
nosis.4 There is, however, no consensus on the optimal
material for patching. Patch angioplasty may be performed
with autologous vein (saphenous or neck vein) or synthetic
material (polytetrafluoroethylene [PTFE] or Dacron).5-8
Proponents of vein patch angioplasty state that the benefits
include no cost, use of autologous tissue, resistance to
infection, and provision of an endothelialized wall to end-
arterectomized areas, although possible disadvantages in-
clude aneurysm formation, early vein patch rupture, and
vein harvest site complications.9-16 The advantages of the
prosthetic patch include immediate availability, no harvest
site complications, low risk for rupture, and preservation of
the saphenous vein, although possible disadvantages in-
clude bleeding through the patch, intraluminal thrombus
formation, and graft infection.17-19 The purpose of this
prospective randomized study was to evaluate the relative
risks and advantages of patching with external jugular vein
(EJV) patch compared with PTFE (Gore-Tex; W. L. Gore
& Associates, Flagstaff, Ariz) at carotid endarterectomy.
The primary end point was the relevant neurologic compli-
cation rate (RNCR; fatal or disabling stroke) at any time
during follow-up. Secondary end points included stroke-
free survival, mortality, and recurrent stenosis rate (50%),
occlusion, patch infection, aneurysm formation, and other
local complications.
The hypothesis was that EJV patching would produce
better results than those with PTFE. This assumption was
based on the theoretical advantage of using autologous
tissue, which offers more resistance to infection and pro-
vides an endothelialized wall, which is less thrombogenic
than a prosthetic graft surface to the flow axis, thereby
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potentially reducing the risk for microembolism and recur-
rent stenosis.
METHODS
Study design. The study was a prospective random-
ized clinical trial carried out at a single center. It was
subdivided into two 3-year periods: December 1996 to
March 1999, when patients were enrolled, and March
1999 to March 2002, which was the follow-up stage. This
study design was chosen to enroll more than 150 patients
operated on by one surgeon over 3 years and to include
follow-up of at least 36 months. Inclusion criteria included
an EJV suitable for patching, defined as a vein diameter 3
mm or larger, with absence of vein branches in a segment at
least 5 cm long, as noted on preoperative color duplex
ultrasound (US) scans obtained with the patient supine in
the Trendelenburg position and holding a deep breath.
The presence of a vein branch was a contraindication to use
of the everted EJV for the carotid patch, because after
eversion intraluminal bumps usually persist, even when 4 or
5/0 ligatures are used. Exclusion criteria included CEA
combined with a cardiac procedure and surgery to treat
recurrent stenosis.
Patients gave informed consent, and were then pro-
spectively randomized 1:1 to receive either an EJV patch or
a synthetic patch.
Randomization was performed by using sealed opaque
envelopes containing indications for EJV or PTFE patch-
ing. The envelopes were put in a container in blocks of 20
(10 EJV; 10 PTFE). An envelope was drawn after admin-
istration of anesthetic was started, and the study controller
notified the surgeon of the procedure to be performed just
before the skin incision was made. All CEAs were per-
formed by the author.
In patients with bilateral carotid artery stenosis only the
first CEA was considered in the analysis; contralateral pro-
cedures were not included.
Before starting the study we calculated the sample size
for each of the two randomized cohorts necessary to eval-
uate this hypothesis. A retrospective review of our data
concerning results of 578 CEAs performed with the PTFE
patch from January 1990 to December 1995 revealed
perioperative RNCR of approximately 2%. On the basis of
these data, 1204 patients (602 in each group) would have
been required to produce a statistically significant differ-
ence. The main assumptions for this calculation were that
the 3-year postoperative RNCR with EJV was expected to
be 1.5% to 2%, slightly better than with PTFE; and the
study power was 80% at P  .05 (log-rank test). We
calculated that to enroll 1204 patients would require 24
years (the principal investigator performed 60 CEAs in 1
year).
Nevertheless we decided to perform a pilot study with a
lesser number of patients and the consequent power limi-
tation, to test the safety of EJV for use as a carotid artery
patch.
The study was approved by the ethics committee at our
institution.
Patients. One hundred seventy-six patients undergo-
ing CEA between December 1996 and March 1999 were
considered eligible. Sixteen patients (9.1%) were excluded
because of lack of an adequate EJV segment as noted on the
preoperative duplex US scan. One hundred sixty patients
were randomized to the two groups; group A patients (n
80) received an EJV patch, and group B patients (n  80)
received a PTFE patch. No crossover between the two
groups was observed; no patient randomized to group A
was rejected intraoperatively because of an inadequate EJV.
Demographic data and preoperative risk factors for the two
groups are presented in Table I. Before surgery all patients
underwent carotid color duplex US scanning, cerebral
computed tomography or magnetic resonance imaging, or
digital subtraction angiography or magnetic resonance an-
giography (MRA). Indications for surgery included hemi-
spheric transient ischemic attack (TIA), nonhemispheric
TIA, amaurosis fugax, and asymptomatic carotid artery
stenosis (Table II).
Operative technique. All CEAs were performed by
the same surgeon (F.G.), with the patient under general
anesthesia, with systemic heparinization, electroencephalo-
Table I. Demographic and clinical data
Group A (EJV) Group B (PTFE)
Pn % n %
Male/female 41/39 58/22 .006
age (y) ( SD)
Mean 70.7  7.1 69.8  7.1 NS
Range 53-89 51-85
Smoking history 35 43.7 45 56.2 NS
Diabetes mellitus 24 30.0 22 27.5 NS
CAD 34 42.5 35 43.7 NS
Hypertension 54 67.5 50 62.5 NS
Hypercholesterolemia 34 42.5 35 43.7 NS
Renal disease (Cr  1.5 mg/dL) 18 22.5 15 18.7 NS
COPD 31 38.7 35 43.7 NS
EJV, External jugular vein; PTFE, polytetrafluoroethylene; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; Cr, creatinine
concentration.
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graphic (EEG) monitoring, and delayed routine shunting
with a Pruitt-Inahara shunt (500-50-9F; Ideas for Medi-
cine, Cryolife Co, St Petersburg, Fla).20 No protamine was
given at the end of the procedure. In group A the EJV was
isolated, and a segment at least 5 cm long was removed.
Before carotid clamping, periadventitial tissue was carefully
removed, and the vein was everted by inserting a small Pean
forceps inside the lumen, so that the intima was on the
outside. The suitability of the venous segment was checked
by pulling the ends in opposite directions; elasticity of the
EJV is usually sufficient that it can be extended one and a
half times its original length. After formation of the patch,
accurate angioplasty depends on the operator knowing that
a flattened cylinder is being used and that there are no real
edges, unlike a PTFE patch. Risk for gathering the end and
changing the geometry of the patch can be prevented by
keeping the opposite, unsutured end in traction. The su-
ture needle must be passed through both venous walls at
the cephalic and caudal ends of the patch to prevent dissec-
tion. In group B a PTFE patch was used, about 7 mm wide
and with a nominal thickness of 0.5 mm. The continuous
suture was completed after removal of the shunt, followed
by careful flushing. An aspiration drain was placed in all
patients. Hemostasis time and blood loss were recorded in
all patients. To limit bleeding, oxidized regenerated cellu-
lose (Surgicel; Johnson & Johnson, North Yorkshire, En-
gland) was used in both groups.
Postoperative assessment and clinical follow-up.
Postoperative treatment included antibiotic therapy for 3
days, and antiplatelet therapy (aspirin, 100 mg/d) starting
on postoperative day 3 and continued after discharge. All
patients were examined postoperatively by a vascular sur-
geon, who was blinded to the type of procedure performed,
and by a neurologist, who documented any neurologic
events. At discharge on postoperative day 4, at 30 days after
surgery, and every 6 months thereafter, all patients under-
went clinical vascular examination and a color duplex US
scanning with a 7.5 mHz probe, with the vessel insonated
at a 60-degree angle. All examinations were performed by a
single operator (M.A.), who was blinded to the type of
closure. Attention was directed to detection of presence of
greater than 50% recurrent stenosis or carotid artery occlu-
sion and to measurement of the maximum diameter of the
carotid bulb. Degree of carotid artery stenosis was assessed
with velocity measurements (peak systolic velocity [PSVIC]
140 cm/s and PSVIC/PSVCC 2 for carotid artery ste-
nosis 50%; PSVIC 200 cm/s and PSVIC/PSVCC 3.2
for carotid artery stenosis70%) and morphologic B-mode
criteria (greatest reduction in area or diameter on multiple
longitudinal and cross-section scans).21 Significant postop-
erative dilatation was defined as increase in bulb diameter of
20% or more at 30 days. Patients with significant recurrent
stenosis or occlusion detected on duplex US scans under-
went MRA for confirmation of the diagnosis.
Complications including death, TIA, reversible isch-
emic neurologic deficit, or stroke, and asymptomatic occlu-
sive events were determined in accordance with the Ad Hoc
Committee Suggested Standards for Reports Dealing with
Cerebrovascular Disease.22
Statistical analysis. Statistical analysis was performed
with the 2 test and Fisher exact test for noncontinuous
variables, the Student t test for continuous variables, and
the log-rank test for Kaplan-Meier and life table analysis.
RESULTS
Between March 1996 and December 1999, 160 CEA
procedures (80 with EJV, group A; 80 with PTFE, group
B) were performed by the principal investigator in a cohort
of 160 randomized patients. In the same period 392 pa-
tients underwent 446 CEA procedures outside of the
study. Randomized patients represent 29.0% of the entire
population that underwent CEA at the Department of
Vascular Surgery, University of Padua.
Other than a gender imbalance (51.25% vs 72.5% male
patients in groups A and B, respectively; P  .006), there
were no statistical differences between demographic and
clinical data for the two groups (Table I). Only one patient
(group A) died, of acute myocardial infarction on postop-
erative day 4 (Table III). Perioperative RNCR was 0% in
group A and 1.25% in group B. One patient in group B had
a postoperative ipsilateral disabling stroke, with normal
perioperative EEG monitoring and normal duplex US scan.
There was no difference in postoperative TIA rate: one
patient in group A (1.25%) and two patients in group B
(2.5%). In group A hemostasis time (0.63 minutes) and
blood loss after declamping (90 mL) were limited. In
contrast, in group B both hemostasis time (mean, 28.5
minutes; range, 14-48 minutes) and blood loss (mean, 350
mL; range, 100-480 mL) were significantly increased (P
.001; Table III). In two patients in group B a cervical
hematoma developed, which necessitated a repeat opera-
tion, but no cervical infection occurred.
Table II. Indication for CEA (preoperative neurologic symptoms)
Group A (EJV) Group B (PTFE)
Pn % n %
Asymptomatic disease 23 28.7 26 32.5 NS
Hemispheric TIA 21 26.2 20 25.0 NS
Amaurosis fugax 7 8.7 9 11.5 NS
Nonhemispheric TIA 23 28.7 20 25.0 NS
Nondisabling stroke 6 7.5 5 6.2 NS
CEA, Carotid endarterectomy; EJV, external jugular vein; PTFE, polytetrafluoroethylene; TIA, transient ischemic attack.
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Follow-up. Follow-up (mean, 47.7 9.1 months for
group A; mean, 45.9  11.5 months for group B; range,
36-64 months) was accomplished in 151 patients (94.4%).
Four patients in group A and five patients in group B died
during the first 36 months of follow-up, of myocardial
infarction (n 5), lung cancer (n 1), and unknown cause
(n 3). With Kaplan-Meier analysis, survival rate (Fig 1) at
6 months was 98.75% for group A and 100% for group B, at
30 months was 93.6% for each group, and at 60 months was
89.3% for group A and 85.0% for group B. No statistical
difference was observed with the log-rank test. All deaths,
except in one in group A, were unrelated to cerebrovascular
events.
RNCR-free rate (Kaplan-Meyer method; Fig 2) at 6
months was 100% for group A and 98.7% for group B
(one postoperative ipsilateral disabling stroke, with pa-
tency of the carotid arteries at MRA), at 30 months was
98.7% for group A (one lethal stroke of unknown cause)
and 94.6% for group B (two new ipsilateral disabling
strokes, thought to be embolic, because MRA scans
demonstrated patency of the carotid arteries; and one
nonipsilateral disabling stroke), and at 60 months re-
mained unchanged. The log-rank test demonstrated no
significant differences.
Stroke-free survival rate was equal to RNCR, that is,
100% at 6 months and 98.7% at 30 months for group A,
and 98.7% at 6 months and 96.3% at 30 months for group
B, and subsequently remained stable (Fig 3). No statistical
differences were observed with the log-rank test.
Two patients in group B (2.5%) and one patient in
group A (1.25%) had asymptomatic thrombosis of the
internal carotid artery, 6 and 24 months after surgery,
respectively. In group B one patient underwent emergent
repeat operation 42 days after surgery, because of a neck
hematoma secondary to suture line rupture; common in-
ternal carotid artery bypass grafting was performed with a
saphenous vein graft. Culture of the PTFE patch was
positive for Staphylococcus aureus.
Table III. Thirty-day perioperative results
Group A (EJV) Group B (PTFE)
Pn % n %
Blood loss (mL)
Mean 90  26 350  91 .001
Range 50-150 100-480
Time to hemostasis (min)
Mean 0.63  0.24 28.5  9.4 .001
Range 0.25-1 14-48
RNCR 0 1 1.25 NS
Ipsilateral TIA 1 1.25 2 2.5 NS
Mortality 1 1.25 0 NS
EJV, External jugular vein; PTFE, polytetrafluoroethylene; RNCR, relevant neurologic complication rate; TIA, transient ischemic attack.
Fig 1. Survival-free rate for groups A (squares) and B (diamonds) at 6-month intervals (Kaplan-Meier method).
Standard error is 8.5% at 60 months for each group. EJV, External jugular vein; PTFE, polytetrafluoroethylene.
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With life table analysis (actuarial method; Fig 4), free-
dom from significant (50%) recurrent stenosis at 6
months was 97.5% for both groups, at 30 months was
93.6% for group A and 92.2% for group B, and at 60
months was 90.2% for group A and 86.7% for group B.
There were no statistical differences with the log-rank test.
In none of these patients was recurrent stenosis greater than
70%. One patient in group A (1.25%) with preoperative
contralateral carotid artery occlusion and asymptomatic,
hemodynamically significant recurrent stenosis greater than
Fig 3. Stroke-free rate for groups A (squares) and B (diamonds) at 6-month intervals (Kaplan-Meier method).
Standard error is 7.1% at 60 months for each group. EJV, External jugular vein; PTFE, polytetrafluoroethylene.
Fig 2. Relevant neurologic complication–free rate (RNCR) for groups A (squares) and B (diamonds) at 6-month
intervals (Kaplan-Meier method). Standard error is 6.2% at 60 months for each group. EJV, External jugular vein;
PTFE, polytetrafluoroethylene.
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50%, caused by myointimal hyperplasia, underwent a sec-
ondary procedure, common carotid–internal carotid artery
bypass grafting with saphenous vein.
No aneurysm formation was observed during follow-
up. Comparison of the 160 randomized patients with the
392 nonrandomized patients revealed no statistical differ-
ences in demographic or clinical data (Table IV), indication
for CEA (Table V), or 30-day postoperative results (Table
VI).
DISCUSSION
The choice of patch material that will provide optimal
results at CEA remains controversial,5-8 and many studies
have been performed in an attempt to resolve this issue.
Gonzalez-Fajardo et al23 performed a randomized study of
95 CEAs with saphenous vein and PTFE patching and
found no significant differences in the incidence of neuro-
logic complication, carotid thrombosis, and recurrent ste-
nosis between the two groups.
In a retrospective review by Goldman et al19 no signif-
icant difference was observed in postoperative mortality,
morbidity, and recurrent stenosis rates in 275 consecutive
CEAs with saphenous vein and Dacron patches. Lord et
al,24 in a prospective randomized series of 140 CEAs, did
not demonstrate statistical difference in postoperative neu-
rologic complications between use of saphenous vein or
PTFE as carotid patch. In a prospective study Katz and
Kohl25 randomized 190 patients to 207 CEAs with Dacron
graft or saphenous vein graft from the thigh, and did not
show significant difference in perioperative stroke between
the two groups. In a prospective randomized trial of CEA
with primary closure and patch angioplasty with saphenous
vein, jugular vein, and PTFE, AbuRahma et al6 demon-
strated in a series of 399 CEAs that patching with either
Fig 4. Freedom from significant recurrent stenosis (50%) for groups A (squares) and B (diamonds) at 6-month
intervals (life table analysis). Standard error is9.99% at 60 months for each group. EJV, External jugular vein; PTFE,
polytetrafluoroethylene.
Table IV. Demographic and clinical data in randomized and nonrandomized patients
Randomized (N  160) Nonrandomized (N  392)
Pn % n %
Male/female 99/61 267/125 NS
Age (y)
Mean  SD 70.3  7.1 70.2  7.3 NS
Range 51-89 45-89
Smoking history 80 50.0 215 54.8 NS
Diabetes mellitus 46 28.7 91 23.2 NS
CAD 69 43.1 154 39.3 NS
Hypertension 104 65.0 278 70.1 NS
Hypercholesterolemia 69 43.1 153 39.0 NS
Renal disease (Cr  1.5 mg/dL) 33 20.6 76 19.4 NS
COPD 66 41.2 184 46.9 NS
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary disease.
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patch material is superior to primary closure in lowering the
incidence of postoperative stroke and in reducing signifi-
cant recurrent carotid artery stenosis. However, no signifi-
cant differences were observed between patch materials.
Jocobowitz et al8 analyzed retrospectively 274 consecutive
CEAs with saphenous vein, internal jugular vein, and knit-
ted Dacron patches, and concluded that the choice of patch
material does not affect early or late stroke, death, and high
(80%) recurrent stenosis rates. In a prospective random-
ized study of saphenous vein versus synthetic patching at
CEA, O’Hara et al7 demonstrated no significant differences
in stroke, mortality, or recurrent stenosis rate between
patch materials in 207 CEAs, and concluded that CEA may
be safely performed with either patch material. AbuRahma
et al5 in a recent prospective randomized study of CEA with
PTFE versus HemaShield patch showed that use of Dacron
patch was associated with a higher incidence of periopera-
tive stroke, carotid thrombosis, and early recurrent stenosis
compared with the PTFE patch. All of these comparative
studies, as well as the present study, are statistically under-
powered, and therefore a definitive conclusion cannot be
made. Moreover, in a collective review of several random-
ized trials of carotid artery patching Counsell et al4 con-
cluded that there is not yet enough evidence in the litera-
ture to enable any definitive conclusions concerning the
advantages of venous versus synthetic patches. Therefore,
because of the low incidence of late stroke and recurrent
stenosis (2%-3%) after CEA with patching, a study with a
much larger cohort of patients will be necessary to demon-
strate the superiority or equivalence of one patch material
over another.
The most frequent criticism of use of venous patch,
usually a segment of the saphenous vein, concerns its
irregularity and mechanical integrity, which may depend on
the site of harvest.12,24 Venous patch is also affected by
anatomic variations and the sequelae of early infection and
trauma, conditions that may make it unsuitable or liable for
aneurysm dilatation (50% increase in transverse diameter)
or rupture in the central patch area along its axial plane. In
contrast, synthetic patch is highly resistant to mechanical
stress, which makes it more resistant to enhanced hemody-
namic stress resulting from the increase in luminal diame-
ter. Thus secondary dilatation is unlikely, and rupture is
rare. In theory, the greatest benefit of using autologous
material is the positive effect on the repair process at the
level of the endarterectomized arterial wall. Margovsky et
al26 used indium 111–labeled platelets to study platelet
deposition in sheep in which a variety of patch materials
were used. These authors showed that thrombocyte adhe-
sion to the endarterectomized surfaces of the blood vessel
repaired with autologous material is significantly lower than
with other synthetic materials (P  .05). They also con-
firmed that the lowest absolute deposition levels occur with
venous patch compared with synthetic material (P  .01).
It can therefore be inferred that acute thrombosis may
occur less frequently when autologous vein is used.
The long saphenous vein is the most common autoge-
nous source for carotid vein patch angioplasty, but it is also
required for coronary artery bypass grafting and lower
extremity revascularization. To save the saphenous vein for
these procedures, other venous material, such as the inter-
nal jugular vein, EJV, and other cervical veins, has been
proposed as an alternative in carotid vein patch angio-
plasty.6 Little has been reported about use of EJV for
carotid patch. Dardik et al27 performed a prospective non-
randomized comparative study of 329 CEAs with saphe-
Table V. Indications for CEA (preoperative neurologic symptoms) in randomized and nonrandomized patients
Randomized (N  160) Nonrandomized (N  132)
Pn % n %
Asymptomatic disease 49 30.6 118 30.1 NS
Hemispheric TIA 41 25.6 89 22.7 NS
Amaurosis fugax 16 10.0 43 10.1 NS
Nonhemispheric TIA 43 26.9 107 27.3 NS
Nondisabling stroke 11 6.9 35 8.9 NS
CEA, Carotid endarterectomy; TIA, transient ischemic attack.
Table VI. Postoperative results (within 30 days) in randomized and nonrandomized patients
Randomized (N  160;
160 operations)
Nonrandomized (N 
392; 446 operations)
Pn % n %
Neurologic mortality 0 0 NS
Ipsilateral stroke 1 .62 5 1.12 NS
RNCR 1 .62 3 0.67 NS
Ipsilateral TIA 3 1.9 6 1.3 NS
Mortality (other causes) 1 .62 3 0.67 NS
RNCR, Relevant neurologic complication rate; TIA, transient ischemic attack.
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nous or everted cervical vein (EJV, common facial vein),
and found no significant difference in rates of postoperative
stroke and recurrent stenosis. In a retrospective review
Sabharwal and Mukherjee28 compared 19 CEAs with EJV
or common facial vein patch with 199 CEAs with saphe-
nous vein patch, and found no statistical difference in
incidence of postoperative mortality, morbidity, cerebro-
vascular accident, or recurrent stenosis.
In December 1996, we first used the EJV patch during
CEA to perform this randomized prospective study of EJV
versus PTFE. The particular design of this prospective
randomized trial was chosen to assess the long-term results
of EJV patching after CEA. After the 3-year enrollment, we
considered another 3 years necessary for follow-up. This
series is the first prospective randomized trial of CEA that
compares use of everted EJV versus PTFE for carotid
closure. The results of our study appear to support those
reported by other centers where this method had been used
for several years. No significant advantages of either patch
have been reported at 60 months for rates of RNCR,
stroke-free survival, postoperative TIA, mortality, and re-
current stenosis. We also found excessive operative bleed-
ing from needle holes in PTFE patch, as has been reported
by others.5,6,29 Reduction of such bleeding has been asso-
ciated with a needle-suture diameter ratio of 1:1, and in our
experience the use of polypropylene sutures (Prolene 5/0)
with RB-1 needles minimized time to hemostasis. Since the
beginning of 2000, a new PTFE patch (Acuseal; W. L.
Gore & Associates) has been available. This patch was
developed to reduce operative bleeding from needle holes.
We now routinely use the new patch at carotid surgery,
with significant reduction in bleeding time.
CONCLUSION
Results of this randomized prospective study confirm
that use of everted and doubled EJV is a safe and useful
method for venous patch closure after endarterectomy.
This small randomized trial was performed with the as-
sumption of a theoretic advantage for this venous patch
compared with a synthetic patch, but no statistical differ-
ences were observed at 30 days and at 6 months for RNCR,
stroke, postoperative TIA, mortality, or recurrent stenosis
(50%). However, the data should be carefully evaluated,
because, in view of the low rate of late RNCR, postopera-
tive TIA, and recurrent stenosis, and the small number of
patients in this comparative prospective study, the statistical
power to detect differences is limited.
We can conclude, despite the power limitation of the
study and while awaiting a larger prospective randomized
trial, that CEA can be safely performed with either EJV or
PTFE patch. In addition, choice of the EJV for carotid
angioplasty has several advantages, including no cost for
material, reduction in blood loss and operating time, lower
risk for graft infection, and preservation of the saphenous
vein.
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